OPAL BIO PHARMA is an innovative Omani healthcare company that is dedicated to protecting and improving people's lives through the miracles of science. As the hub of health for Arab society, they bring essential medicine and vaccines to the GCC and MENA regions. Supported by key investors such as Saal Al Junaibi, Zubair Corporation, Saad Suhail, and his sons, OPAL BIO PHARMA is committed to making their vision a reality.

Their strategy revolves around scientific innovation, focusing on biosimilar vaccines, specialty medicines with mAb technology, and gene therapy opportunities. By prioritizing R&D in the science of the immune system, human genetics, and advanced technologies, they are at the forefront of medical advancements.

OPAL BIO PHARMA's areas of focus include vaccines, oncology, and gene therapy. They develop a broad portfolio of vaccines to protect against various infectious diseases, while also dedicated to advancing cancer medicines and personalized gene therapy treatments.

With a strong pipeline and a culture driven by united individuals, OPAL BIO PHARMA strives to push the boundaries of science and make a better world for all.